13-Mar-2026
Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors
TipRanks (Thu, 12-Mar 12:30 PM ET)
TipRanks (Wed, 11-Mar 9:30 AM ET)
TipRanks (Wed, 11-Mar 6:20 AM ET)
PRNewswire (Tue, 10-Mar 7:00 AM ET)
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
PRNewswire (Wed, 4-Mar 8:00 AM ET)
PRNewswire (Tue, 3-Mar 8:00 AM ET)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PRNewswire (Mon, 2-Mar 9:30 AM ET)
PRNewswire (Thu, 26-Feb 8:00 AM ET)
PRNewswire (Thu, 5-Feb 8:00 AM ET)
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
PRNewswire (Tue, 13-Jan 8:00 AM ET)
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Edgewise Therapeutics trades on the NASDAQ stock market under the symbol EWTX.
As of March 13, 2026, EWTX stock price declined to $29.59 with 649,872 million shares trading.
EWTX has a beta of 2.64, meaning it tends to be more sensitive to market movements. EWTX has a correlation of 0.25 to the broad based SPY ETF.
EWTX has a market cap of $3.13 billion. This is considered a Mid Cap stock.
In the last 3 years, EWTX traded as high as $38.12 and as low as $5.12.
The top ETF exchange traded funds that EWTX belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
EWTX has underperformed the market in the last year with a return of +17.0%, while SPY returned +21.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in EWTX shares. However, EWTX has outperformed the market in the last 3 month and 2 week periods, returning +25.3% and -2.8%, while SPY returned -2.6% and -3.5%, respectively. This indicates EWTX has been having a stronger performance recently.
EWTX support price is $28.92 and resistance is $30.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EWTX shares will trade within this expected range on the day.
